Quickly reference insurance provider coverage of SGLT-2 Inhibitors and GLP1-Receptor Agonists as well as CGMs. Providers include private Blue Cross Blue Shield of Michigan, HAP, Priority Health, and United Plans, as well as public Medicare, Medicare Advantage, and Medicaid coverage. Pharmacy carve out coverage information is forthcoming.
Developed by the Michigan Collaborative for Type 2 Diabetes.
Support for the Michigan Collaborative on Type 2 Diabetes is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs. To learn more about Value Partnerships, visit www.valuepartnerships.com. Although Blue Cross Blue Shield of Michigan and the Michigan Collaborative on Type 2 Diabetes work in partnership, the opinions, beliefs, and viewpoints expressed by MCT2D do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.